Certara Launches Cardiac Safety Simulator V2.0

Article

Applied Clinical Trials

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies.

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies. CSS uses drug-triggered cardiac ion-current disruption data, together with predicted in-vivo exposure information to evaluate the factors influencing potential cardiac risk.

CSS v2.0 offers new features including the following:

  • Enhanced QSAR models for predicting drug-triggered IKr, IKs, INa and ICaL current inhibition based on automatically-calculated phys-chem data (when in-vitro data are not available)

  • Predicts population variability and drug-triggered physiology modifications

  • Permits assessment of the potential impact of disease and genotypes; allows for genotype-related ionic current modification at the multiple channels level

  • Contains an additional human left ventricular muscle cell model

  • Evaluates up to seven chemical species (drugs, metabolites and other substances) simultaneously that are interacting at the ion channel(s) level

  • Provides a new flexible, Excel-based tool to enhancevisualization and analysis of simulation results

 

 

Read the full release.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
Related Content
© 2024 MJH Life Sciences

All rights reserved.